Loading

Turning AI Hype into Real-World Breakthroughs and Measurable Value for Pharma

June 24, 2026
31AB
Type: Breakout Session
Focus Area: AI and Digital Health
AI has moved from concept to execution in drug discovery, but turning algorithms into actionable insights requires deep scientific alignment and cross-functional integration. This session brings together leaders from pharmaceutical and techbio companies to discuss how AI is redefining discovery, validation, and collaboration models across the biopharma ecosystem. Panelists will explore what it truly takes to make AI deliver measurable impact - building high-quality datasets, designing interpretable generative models, and translating predictions into experimentally validated outcomes. The conversation will also address how pharma and AI-native companies can collaborate more effectively, balancing innovation speed, data governance, and scientific credibility.

Subtopic

AI for Drug Discovery
Moderator
David Del Bourgo, MBA
CEO & Cofounder
WhiteLab Genomics
Speakers
Michelle Chen, PhD
President & Chief Executive Officer
FormBio
Cynthia Hong, PhD
AI & Discovery Sciences, Search & Evaluation Business Development
Novartis
Eric Kelsic, PhD
CEO & Cofounder
Dyno Therapeutics
Jean Frederic Petit Nivard, MSc
Chief Business Development Officer
Owkin
Sarah Tao, PhD
Head of Search & Evaluation, Technology Platforms, Partnering, Global BD&L
Sanofi

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS

Loading